PURA - Puration Positions To Harness $1.4 Billion Global CBD Beverage Market

December 06, 2019 9:14 AM EST | Source: Puration Inc.

Dallas, Texas--(Newsfile Corp. - December 6, 2019) - Puration, Inc. (OTC Pink: PURA) today confirmed closing a business acquisition in Bogota, Colombia yesterday to enable PURA to bottle CBD beverages in Latin America for the Latin American market. PURA recently closed an acquisition to enable PURA to bottle CBD Beverages in Europe for the European market. PURA already has access to bottling in North America and Africa. The CBD beverage market is one of the fastest growing beverage sectors anticipated to reach $1.4 billion by 2023.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6696/50506_5d51a22004732a38_001.jpg

U.S. CBD Beverage Market Value 2018 - 2023

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6696/50506_5d51a22004732a38_001full.jpg

The overall legal Latin American cannabis market is anticipated to reach $9 billion by 2028. The European market for CBD is projected to reach nearly US $17 billion by 2023. With the acquisition announced yesterday, PURA is well positioned to harness the global market for CBD beverages. PURA has recently reconfirmed its $4 million revenue target for 2019 and an $8 million revenue target for 2020.

For more information on Puration, visit http://www.purationinc.com

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/50506

info